clofibric acid has been researched along with Elevated Cholesterol in 47 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 7.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 5.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| "In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III)." | 3.67 | [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. ( Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A, 1989) |
| "All patients with type 2 diabetes should reach an LDL cholesterol of <100 mg/dl, the very-high risk patients with both diabetes and coronary artery disease an LDL cholesterol <70 mg/dl." | 2.46 | [Lipid therapy in patients with diabetes]. ( Drexel, H; Saely, CH, 2010) |
| "Ursodeoxycholic acid the standard treatment of primary biliary cirrhosis improves the cholestasis and hereby lowers circulating levels of cholesterol." | 2.44 | Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. ( Balmer, ML; Dufour, JF, 2008) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "4%) achieved goal following treatment changes, including upward dosage adjustments." | 1.34 | Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. ( Márk, L; Ofner, P; Pados, G; Paragh, G; Zámolyi, K, 2007) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | 1.33 | [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| "Ciprofibrate is a hypolipidaemic compound that acts primarily by enhancing the oxidation of fatty acids in the liver and, consequently, decreasing the production of hepatic VLDL." | 1.32 | The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. ( Borensztajn, J; Fu, T; Kashireddy, P, 2003) |
| "Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively)." | 1.29 | Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. ( Bruckert, E; Chapman, MJ; Dejager, S, 1993) |
| "Treatment with etofibrate led to a marked decrease in total cholesterol and LDL-cholesterol." | 1.28 | Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation. ( Burkard, M; Huth, K; Quack, G; Richter, CM; Wülfroth, P, 1992) |
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 1.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (31.91) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 20 (42.55) | 29.6817 |
| 2010's | 2 (4.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gadarla, M | 1 |
| Kearns, AK | 1 |
| Thompson, PD | 1 |
| Balmer, ML | 1 |
| Dufour, JF | 1 |
| Moulin, P | 1 |
| Ferrières, J | 1 |
| Gousse, ET | 1 |
| Fabry, C | 1 |
| Hermans, MP | 1 |
| Lahoz, C | 1 |
| Mostaza, JM | 1 |
| Cohen, H | 1 |
| Bielorai, B | 1 |
| Harats, D | 1 |
| Toren, A | 1 |
| Pinhas-Hamiel, O | 1 |
| Saely, CH | 1 |
| Drexel, H | 1 |
| Fu, T | 2 |
| Kashireddy, P | 1 |
| Borensztajn, J | 2 |
| Kastelein, J | 1 |
| HELLMAN, L | 1 |
| ZUMOFF, B | 1 |
| KESSLER, G | 1 |
| KARA, E | 1 |
| RUBIN, IL | 1 |
| ROSENFELD, RS | 1 |
| Kozarsky, KF | 1 |
| Devroey, D | 1 |
| Velkeniers, B | 1 |
| Duquet, W | 1 |
| Betz, W | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Herman, ZS | 1 |
| Dunbar, RL | 1 |
| Rader, DJ | 1 |
| Klose, G | 1 |
| Jancsó, Z | 1 |
| Varga, Z | 1 |
| Simay, A | 1 |
| Ilyés, I | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Geiss, HC | 1 |
| Parhofer, K | 1 |
| Rigotti R, A | 1 |
| Arteaga Ll, A | 1 |
| Maiz G, A | 1 |
| Zvenigorodskaia, LA | 1 |
| Mel'nikova, NV | 1 |
| Bondarenko, EIu | 1 |
| Paragh, G | 1 |
| Márk, L | 1 |
| Zámolyi, K | 1 |
| Pados, G | 1 |
| Ofner, P | 1 |
| Abdel-Maksoud, M | 1 |
| Sazonov, V | 1 |
| Gutkin, SW | 1 |
| Hokanson, JE | 1 |
| Słowińska, R | 1 |
| Bochenek, W | 1 |
| Unlot, J | 1 |
| Canzler, H | 1 |
| Mordasini, R | 2 |
| Riesen, W | 2 |
| Oster, P | 2 |
| Keller, M | 1 |
| Middelhoff, G | 1 |
| Lang, PD | 1 |
| Marín Plaza, R | 1 |
| Díaz González, JM | 1 |
| Varela de Seijas, JR | 1 |
| Riva, G | 1 |
| Davignon, J | 1 |
| Lussier-Cacan, S | 1 |
| Dubreuil-Quidoz, S | 1 |
| LeLorier, J | 1 |
| Reuter, W | 1 |
| Fringes, B | 1 |
| Riede, UN | 1 |
| von Deimling, O | 1 |
| Mertz, DP | 1 |
| Devuyst, O | 2 |
| Goffin, E | 2 |
| Pirson, Y | 2 |
| van Ypersele de Strihou, C | 2 |
| Bruckert, E | 1 |
| Dejager, S | 1 |
| Chapman, MJ | 1 |
| Shepherd, J | 2 |
| Muls, E | 1 |
| Van Gaal, L | 1 |
| Autier, P | 1 |
| Vansant, G | 1 |
| Priego, JG | 1 |
| Maroto, ML | 1 |
| Piña, M | 1 |
| Catalán, RE | 1 |
| Rahlfs, VW | 1 |
| Zimmermann, H | 1 |
| Safer, A | 1 |
| Wülfroth, P | 1 |
| Richter, CM | 1 |
| Burkard, M | 1 |
| Huth, K | 1 |
| Quack, G | 1 |
| Perault, MC | 1 |
| Fievre, JL | 1 |
| Dejean, C | 1 |
| Martin, A | 1 |
| Vandel, B | 1 |
| Sallustio, BC | 1 |
| Knights, KM | 1 |
| Roberts, BJ | 1 |
| Zacest, R | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Michel, G | 1 |
| Bouckaert, A | 1 |
| Dembińska-Kieć, A | 1 |
| Kostka-Trabka, E | 1 |
| Grodzińska, L | 1 |
| Bieroń, K | 1 |
| Kedzior, A | 1 |
| Basista, M | 1 |
| Zmuda, A | 1 |
| Trabka, E | 1 |
| Slawiński, M | 1 |
| Czarnecka, H | 1 |
| Series, JJ | 1 |
| Caslake, MJ | 1 |
| Kilday, C | 1 |
| Cruickshank, A | 1 |
| Demant, T | 1 |
| Packard, CJ | 1 |
| Simpson, IA | 1 |
| Lorimer, AR | 1 |
| Walker, ID | 1 |
| Davidson, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for clofibric acid and Elevated Cholesterol
| Article | Year |
|---|---|
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2008 |
[HDL-cholesterol: from risk factor to therapeutic target].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypercholesterolemia; Niacin; Ris | 2009 |
[Lipid therapy in patients with diabetes].
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dose-Response Relatio | 2010 |
What future for combination therapies?
Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp | 2003 |
Demystifying triglycerides: a practical approach for the clinician.
Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2005 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Arter | 2006 |
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Humans | 2008 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
7 trials available for clofibric acid and Elevated Cholesterol
| Article | Year |
|---|---|
Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Topics: Adult; Anticholesteremic Agents; C-Reactive Protein; Clofibric Acid; Cytokines; Diabetes Mellitus, T | 2005 |
[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
Topics: Carbohydrate Metabolism; Clofibric Acid; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 2007 |
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; | 1983 |
[Clinical trial of a new drug for the treatment of atherosclerosis: pirozadil (722-D) (author's transl)].
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Female; Humans; Hypercholesterolemia; Hy | 1982 |
[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Topics: Adult; Apoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibric Acid; Colestipol; Humans; | 1982 |
[Etofibrate and clofibrate in double blind study].
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hypercholest | 1976 |
[An epidemiological study of hypercholesterolemia in the Grand Duchy of Luxembourg].
Topics: Adult; Aged; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Epidemiologic Methods; Female; Fib | 1990 |
30 other studies available for clofibric acid and Elevated Cholesterol
| Article | Year |
|---|---|
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; C | 2008 |
CEPHEUS Trial.
Topics: Anticholesteremic Agents; Clofibric Acid; Drug Utilization; Guideline Adherence; Humans; Hydroxymeth | 2008 |
Assessment of lipid-lowering treatment in France--the CEPHEUS study.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Utilization; Europe; Family Practice; | 2008 |
Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chi | 2010 |
The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Blotting, Northern; Blotting, Western; Clofibric Acid; F | 2003 |
REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE.
Topics: Butyrates; Cholesterol; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Male | 1963 |
Overexpression of SR-BI by adenoviral vector reverses the fibrateinduced hypercholesterolemia of apolipoprotein E-deficient mice.
Topics: Adenoviridae; Animals; Apolipoproteins E; CD36 Antigens; CHO Cells; Cholesterol; Clofibric Acid; Cri | 2003 |
The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; H | 2005 |
[New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Dose-Response R | 2005 |
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity | 2005 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |
Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Cost-Benefit A | 2007 |
Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few...
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA R | 2005 |
[Drug therapy of hypercholesterinemias (author's transl)].
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; | 1980 |
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Bezafibrat | 1981 |
Experience with probucol in the treatment of hypercholesterolemia.
Topics: Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Ag | 1982 |
[Current treatment with clofibrate or clofibric acid (Regadrin)].
Topics: Cholelithiasis; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipoprot | 1982 |
Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; H | 1982 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hyperc | 1980 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hy | 1994 |
Creatinine rise after fibrate therapy in renal graft recipients.
Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterol | 1993 |
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Clofibric Acid; Fibric Acids; Humans; Hypercholester | 1993 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholes | 1997 |
Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.
Topics: Animals; Clofibrate; Clofibric Acid; Diet; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; | 1979 |
Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.
Topics: Animals; Cholesterol, Dietary; Cholesterol, LDL; Clofibric Acid; Female; Humans; Hypercholesterolemi | 1992 |
[Cytolytic hepatic damage caused by ciprofibrate].
Topics: Aged; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fibric Acids; Humans; Hypercho | 1992 |
In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins.
Topics: Animals; Blood Proteins; Clofibric Acid; Creatinine; Glucuronates; Humans; Hypercholesterolemia; Liv | 1991 |
[Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Topics: Adult; Arteriosclerosis Obliterans; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hy | 1989 |
Influence of etofibrate on low density lipoprotein metabolism.
Topics: Adult; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; L | 1988 |
Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
Topics: Adult; Alkaline Phosphatase; Cholesterol; Clofibrate; Clofibric Acid; Fibric Acids; Fibrinogen; Fibr | 1985 |